Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Maaike de Fost"'
Autor:
Maaike de Fost, Carel J.M. van Noesel, Johannes M.F.G. Aerts, Mario Maas, Ruud G. Pöll, Carla E.M. Hollak
Publikováno v:
Haematologica, Vol 93, Iss 7 (2008)
Externí odkaz:
https://doaj.org/article/7766b722093c481eaa82ec35c5a6ab0c
Autor:
Maaike de Fost, Johannes M.F.G. Aerts, Johanna E.M. Groener, Mario Maas, Erik M. Akkerman, Maaike G. Wiersma, Carla E.M. Hollak
Publikováno v:
Haematologica, Vol 92, Iss 2 (2007)
Background and Objectives Gaucher disease type I can be successfully treated with enzyme replacement therapy (ERT). In order to reduce the burden of the intravenously administered enzyme, a low frequency of administration was prospectively studied in
Externí odkaz:
https://doaj.org/article/63669ca95a664832938d3729c679163c
Autor:
Arjen M. Dondorp, Tom van der Poll, Nicholas J. White, Maaike de Fost, Kriangsak Pimda, Wirongrong Chierakul
Publikováno v:
Scopus-Elsevier
American journal of tropical medicine and hygiene, 72(4), 465-467. American Society of Tropical Medicine and Hygiene
American journal of tropical medicine and hygiene, 72(4), 465-467. American Society of Tropical Medicine and Hygiene
Thai patients with scrub typhus caused by the intracellular pathogen Orientia tsutsugamushi displayed elevated plasma concentrations of granzymes A and B, interferon-gamma (IFN)-gamma-inducible protein 10, and monokine induced by IFN-gamma. These dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3816ea1abbc14dd8bcab58e478bab1
https://ora.ox.ac.uk/objects/uuid:431f9203-4574-4357-bc47-9a6d1d030300
https://ora.ox.ac.uk/objects/uuid:431f9203-4574-4357-bc47-9a6d1d030300
Autor:
Laura van Dussen, Carla E. M. Hollak, Maaike de Fost, Stephan vom Dahl, Johannes M. F. G. Aerts
Publikováno v:
Expert opinion on pharmacotherapy. 10(16):2641-2652
BACKGROUND: Enzyme therapy for Gaucher disease has improved the lives of many patients, by reducing the burden of their disease. Several studies have sought to determine to what extent optimal clinical outcomes are a function of the prescribed enzyme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859f1c1d55a1ad6a68928009e8037a15
https://doi.org/10.1517/14656560903270520
https://doi.org/10.1517/14656560903270520
Autor:
Carla E. M. Hollak, Mario Maas, Jane S. A. Voerman, Johannes M. F. G. Aerts, Rolf G. Boot, Maaike de Fost, Mariëlle J. van Breemen, Farhad Rezaee, Jon D. Laman
Publikováno v:
Biochimica et Biophysica Acta-Molecular Basis of Disease, 1772(7), 788-796. Elsevier
ResearcherID
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1772(7), 788-796. Elsevier
Biochimica et Biophysica Acta: Molecular Basis of Disease, 1772(7), 788-796
ResearcherID
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1772(7), 788-796. Elsevier
Biochimica et Biophysica Acta: Molecular Basis of Disease, 1772(7), 788-796
Pancytopenia, hepatosplenomegaly and skeletal complications are hallmarks of Gaucher disease. Monitoring of the outcome of therapy on skeletal status of Gaucher patients is problematic since currently available imaging techniques are expensive and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e436f27db8bd72c115c23b4d4415a2f
https://doi.org/10.1016/j.bbadis.2007.04.002
https://doi.org/10.1016/j.bbadis.2007.04.002
Publikováno v:
European Journal of Haematology. 72:135-139
Recently, soluble CD163 (sCD163) has been identified as a macrophage/monocyte-specific plasma protein and increased concentrations have been measured in patients with infection and myeloid leukaemia. In the present study we investigated the levels of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8088bdb1aee33947ef7e6006523829c8
https://doi.org/10.1046/j.0902-4441.2003.00193.x
https://doi.org/10.1046/j.0902-4441.2003.00193.x
Publikováno v:
Clinical and diagnostic laboratory immunology, 10(2), 332-335. American Society for Microbiology
Heat-killed pathogenicLeptospira interrogansserovar rachmati induced the production of gamma interferon (IFN-γ) and the IFN-γ-inducing cytokines interleukin-12p40 (IL-12p40) and tumor necrosis factor alpha in human whole blood in vitro. The product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f37b6eaf1fbdccccf5ddca0119a04c43
https://doi.org/10.1128/cdli.10.2.332-335.2003
https://doi.org/10.1128/cdli.10.2.332-335.2003
Autor:
Jesús Villarubia, Elena Zhukovskaya, Maria Domenica Cappellini, Hanna Rosenbaum, Dragana Janic, Carla E. M. Hollak, Jan Van Droogenbroeck, Theodore Marinakis, Derralynn Hughes, Marc G. Berger, Maaike de Fost
Publikováno v:
Clinical Therapeutics. 29:S88-S90
S88 Volume 29 Supplement C Hematologic and Hemato-Oncologic Aspects of Gaucher Disease Derralynn Hughes, MA, DPhil, MRCP, MRCPath1; Maria Domenica Cappellini, MD2; Marc Gabriel Berger, MD, PhD3; Jan Van Droogenbroeck, MD4; Maaike de Fost, MD5; Dragan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4e7bd7dce4e2fd036520cc32bad04e2
https://doi.org/10.1016/s0149-2918(07)80461-9
https://doi.org/10.1016/s0149-2918(07)80461-9
Autor:
Carla E. M. Hollak, Mario Maas, Johannes M. F. G. Aerts, Carel J. M. van Noesel, Maaike de Fost, Ruud G Pöll
Publikováno v:
Haematologica, 93(7), 1119-1120
Haematologica, 93(7), 1119-1120. Ferrata Storti Foundation
ResearcherID
de Fost, M, van Noesel, C J, Aerts, J M, Maas, M, Poll, R G & Hollak, C E 2008, ' Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy ', Haematologica, vol. 93, no. 7, pp. 1119-1120 . https://doi.org/10.3324/haematol.12651
Haematologica, 93(7), 1119-1120. Ferrata Storti Foundation
ResearcherID
de Fost, M, van Noesel, C J, Aerts, J M, Maas, M, Poll, R G & Hollak, C E 2008, ' Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy ', Haematologica, vol. 93, no. 7, pp. 1119-1120 . https://doi.org/10.3324/haematol.12651
In Gaucher disease type I (GD, OMIM #230800), deficient activity of the enzyme glucocerebrosidase results in hepatosplenomegaly, cytopenia and skeletal disease.[1][1] Skeletal disease leads to chronic bone pain and/or severe complications such as pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d1e7e59573e3ca918dcb0fee2422f8
http://www.haematologica.org/content/93/7/1119
http://www.haematologica.org/content/93/7/1119
Autor:
Hanna Rosenbaum, Elena Zhukovskaya, Jan Van Droogenbroeck, Derralynn Hughes, Marc Berger, Maria Domenica Cappellini, Jesús Villarubia, Theodore Marinakis, Maaike de Fost, Dragana Janic, C. E. M. Hollak
Publikováno v:
British journal of haematology. 138(6)
Current knowledge of the haematological and onco-haematological complications of type 1 Gaucher disease has been reviewed with the aim of identifying best clinical practice for treatment and disease management. It was concluded that: (i) Awareness of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bada11b264fe4c204bf310c219e028a0
https://pubmed.ncbi.nlm.nih.gov/17655726
https://pubmed.ncbi.nlm.nih.gov/17655726